Proxy Votes Now

Home › Funds › Vanguard › Vanguard Health Care Fund

Vanguard Health Care Fund (VGHAX) proxy voting record 2025-2026

Fund family: Vanguard · Filed by VANGUARD SPECIALIZED FUNDS (CIK 734383) · SEC series S000002922

Share classes and tickers: VGHAX (C000008008), VGHCX (C000008007)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 879 with, 15 against, 6 abstentions (not counted as with management); 29 items carried no recommendation. Shareholder proposals: 5 FOR, 10 AGAINST, 5 abstained, by the filing’s own vote-source field.

Compared with Vanguard as a whole

The same two figures as Vanguard’s manager page (1,379,791 ballot items across 136 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsVanguardItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)98.0%79694.5%1,082,514
Backed environmental and social shareholder proposals at US companiesn/a60.9%6,718

Where this fund voted differently from most Vanguard funds

Each ballot item this fund voted is set against the votes of the other Vanguard funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Vanguard funds on 12 items (2.1% of the 560 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Vanguard fundsMgmtResult
Bristol-Myers Squibb Company2026-05-05Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorForAGAINST — 33 of 33 Vanguard fundsAgainstNot approved, 27.6% support
Bristol-Myers Squibb Company2026-05-05Election of Directors: Derica W. RiceAgainstFOR — 34 of 34 Vanguard fundsAgainstElected, 97.2% support
Boston Scientific Corporation2026-04-30Proposal to elect ten Directors: David C. HabigerAgainstFOR — 27 of 27 Vanguard fundsAgainstElected, 85.9% support
Boston Scientific Corporation2026-04-30Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."ForAGAINST — 27 of 28 Vanguard fundsAgainstNot approved, 42.8% support
Incyte Corporation2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerAgainstFOR — 25 of 26 Vanguard fundsAgainstElected, 80.9% support
Avantor, Inc.2026-05-07Election of Directors: Gregory SummeAgainstFOR — 16 of 16 Vanguard fundsAgainstPassed (calculated), 87.0% support
Madrigal Pharmaceuticals, Inc.2026-06-17Re-election of Class I directors: Julian BakerWithholdFOR — 15 of 15 Vanguard fundsAgainstElected, 88.6% support
AbbVie Inc.2026-05-08Shareholder Stockholder proposal - to adopt a policy to require an independent chairForAGAINST — 29 of 31 Vanguard fundsAgainstNot approved, 39.6% support
Mineralys Therapeutics, Inc.2026-05-21Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D.ForWITHHOLD — 12 of 12 Vanguard fundsForPassed (calculated), 60.6% support
Vertex Pharmaceuticals Incorporated2026-05-13Shareholder Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.ForAGAINST — 21 of 23 Vanguard fundsAgainstApproved, 57.0% support
Eli Lilly and Company2026-05-04Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair.ForAGAINST — 27 of 37 Vanguard fundsAgainstNot approved, 33.7% support
Moderna, Inc.2026-05-06To approve, on a non-binding, advisory basis, the compensation of our named executive officers.AgainstFOR — 17 of 30 Vanguard fundsAgainstApproved, 65.1% support

Download all 12 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 64.3% of this fund’s 900 such votes could be given a sector; the other 321 (35.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care517142.7%
Industrials4500.0%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5590
Corporate Governance865
Audit-related820
Say-on-Pay660
Capital Structure610
Compensation580
Shareholder Rights and Defenses124
Other Social Issues74
Extraordinary Transactions30
Diversity, Equity, and Inclusion11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$10.4B102
Merck & Co., Inc.May 26, 2026$5.1B183
Edwards Lifesciences CorporationMay 7, 2026$3.3B120
UnitedHealth Group IncorporatedJune 1, 2026$3.3B121
Johnson & JohnsonApril 23, 2026$3.0B151
Danaher CorporationMay 5, 2026$2.2B140
Abbott LaboratoriesApril 24, 2026$2.1B160
Cencora, Inc.March 5, 2026$2.0B130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder proposal - to adopt a policy to require an independent chair Shareholder proposalForAgainst
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
May 13, 2026Elevance Health, Inc.Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposalAgainstFor
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposalAgainstFor
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding shareholders' right to act by written consent. Shareholder proposalAgainstFor

Search this fund’s votes by company

936 ballot items at 91 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Vanguard Health Care Fund (VGHAX) voted at 91 shareholder meetings of 81 companies, on 936 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 15 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 20 shareholder proposals. It voted FOR the board's own proposals more often than Vanguard's funds as a whole (98.0% against 94.5%). It voted differently from most Vanguard funds on 12 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Vanguard’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.